Christopher James Sampson : Citation Profile

Office of Health Economics

3

H index

0

i10 index

13

Citations

RESEARCH PRODUCTION:

8

Articles

11

Papers

RESEARCH ACTIVITY:

   11 years (2013 - 2024). See details.
   Cites by year: 1
   Journals where Christopher James Sampson has often published
   Relations with other researchers
   Recent citing documents: 2.    Total self citations: 1 (7.14 %)

EXPERT IN:

   Health
   Publicly Provided Goods
   Welfare Economics

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/psa1048
   Updated: 2026-05-02    RAS profile: 2026-01-13    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers

Works with:

Towse, Adrian (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Christopher James Sampson.

Is cited by:

Dubois, Pierre (1)

Magnac, Thierry (1)

Lorgelly, Paula (1)

Sculpher, Mark (1)

Shah, Koonal (1)

Cites to:

Brazier, John (4)

Devlin, Nancy (4)

Frew, Emma (3)

Brouwer, Werner (3)

Cubi-Molla, Patricia (2)

Straume, Odd Rune (2)

Brekke, Kurt (2)

Niessen, Louis (2)

Parkin, David (2)

Tsuchiya, Aki (2)

Ferrer-i-Carbonell, Ada (1)

Main data

Where Christopher James Sampson has published?

Journals with more than one article published# docs
PharmacoEconomics - Open2

Working Papers Series with more than one paper published# docs
Contract Research / Office of Health Economics4
MPRA Paper / University Library of Munich, Germany3
Grant-Funded Research / Office of Health Economics2
Briefing / Office of Health Economics2

Recent works citing Christopher James Sampson (2025 and 2024)

YearTitle of citing document
2024Optimal intertemporal curative drug expenses: The case of hepatitis C in France. (2024). Magnac, Thierry ; Dubois, Pierre. In: Journal of Health Economics. RePEc:eee:jhecon:v:94:y:2024:i:c:s0167629624000067.

Full description at Econpapers || Download paper

2024‘Managing values’ in health economics modelling: Philosophical and practical considerations. (2024). Winsberg, Eric B ; Harvard, Stephanie. In: Social Science & Medicine. RePEc:eee:socmed:v:358:y:2024:i:c:s027795362400710x.

Full description at Econpapers || Download paper

Works by Christopher James Sampson:

YearTitleTypeCited
2024Marginal cost per QALY estimates: What are they good for? In: Health Policy.
[Full Text][Citation analysis]		article0
2019How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy In: Briefing.
[Citation analysis]		paper3
2021How is Quality of Life Measured for Health Technology Assessments? In: Briefing.
[Full Text][Citation analysis]		paper0
2018Barriers to Uptake of Minimal Access Surgery in the United Kingdom In: Contract Research.
[Full Text][Citation analysis]		paper0
2018The Impact of New Medicines in the NHS: 70 Years of Innovation In: Contract Research.
[Full Text][Citation analysis]		paper0
2023The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe In: Contract Research.
[Full Text][Citation analysis]		paper0
2024A Framework for Value-aligned Pricing of Combination Therapies In: Contract Research.
[Full Text][Citation analysis]		paper0
2018R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C In: Grant-Funded Research.
[Full Text][Citation analysis]		paper1
2020Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation? In: Grant-Funded Research.
[Full Text][Citation analysis]		paper0
2013Cost implications of treatment non-completion in a forensic personality disorder service In: MPRA Paper.
[Full Text][Citation analysis]		paper0
2013Happy and healthy: a joint model of health and life satisfaction In: MPRA Paper.
[Full Text][Citation analysis]		paper0
2013The relationship between individual risk and cost-effectiveness in screening interventions In: MPRA Paper.
[Full Text][Citation analysis]		paper0
2021Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al. In: Medical Decision Making.
[Full Text][Citation analysis]		article1
2022Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy In: Applied Health Economics and Health Policy.
[Full Text][Citation analysis]		article0
2013Do patients registered with CAM-trained GPs really use fewer health care resources and live longer? A response to Kooreman and Baars. Eur J Health Econ (2012). 13:469–776 In: The European Journal of Health Economics.
[Full Text][Citation analysis]		article0
2019Transparency in Decision Modelling: What, Why, Who and How? In: PharmacoEconomics.
[Full Text][Citation analysis]		article4
2017Model Registration: A Call to Action In: PharmacoEconomics - Open.
[Full Text][Citation analysis]		article4
2022NICE and the EQ-5D-5L: Ten Years Trouble In: PharmacoEconomics - Open.
[Full Text][Citation analysis]		article0
2024Is anchoring at ‘dead’ a theoretical requirement for health state valuation? In: Health Economics.
[Full Text][Citation analysis]		article0

CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated March, 14 2026. Contact: CitEc Team